Stay informed on the latest Truth Social posts from Donald Trump (@realDonaldTrump) without the doomscrolling. Consider it a public service for your mental health. (Why?)
Filtering by entity: American Patients | Clear Filter
Summary:A letter from The White House, signed by Donald J. Trump and dated July 31, 2025, addresses AbbVie and other drug manufacturers, stating an Executive Order from May 12, 2025, aims to implement Most-Favored-Nation (MFN) drug pricing for American patients, demanding that US drug prices match those in other developed nations. The letter outlines specific demands for drug manufacturers, including extending MFN pricing to Medicaid, guaranteeing it for newly-launched drugs, repatriating foreign revenues, and participating in direct purchasing models, with a deadline for compliance by September 29, 2025, and a warning of further action if compliance is not met.
Sentiment:Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to deliver Most-Favored-Nation (MFN) prescription drug pricing to American patients.
- American brand name drug prices are up to three times higher than elsewhere, a result of 'global freeloading'.
- The Administration rejects policy changes that would result in 'billions of dollars in handouts to industry'.
- AbbVie and other drug manufacturers are called to extend MFN pricing to Medicaid for existing drugs.
- Drug manufacturers must guarantee MFN pricing for newly-launched drugs to Medicare, Medicaid, and commercial payers.
- Increased revenues generated abroad must be repatriated to lower drug prices for American patients and taxpayers.
- Drug manufacturers should provide for Direct Purchasing at MFN pricing via Direct-to-Consumer (DTC) and/or Direct-to-Business (DTB) models.
- The Administration will 'deploy every tool in our arsenal' if drug manufacturers do not comply with the demands.
- Binding commitments to meet these goals are expected by September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:7/10
Summary:The post consists of a letter from Donald Trump, dated July 31, 2025, addressed to Christopher Boerner of Bristol Myers Squibb, outlining demands for pharmaceutical companies to lower drug prices for American patients. The letter states that an Executive Order was signed on May 12, 2025, to ensure Americans pay the same drug prices as other developed nations, asserting that U.S. prices are currently up to three times higher due to other nations 'freeloading' on American innovation. It demands specific actions within 60 days, including extending Most-Favored-Nation (MFN) pricing to Medicaid and new drugs, repatriating increased revenues from abroad to lower U.S. prices, and providing for direct purchasing at MFN pricing. The letter indicates that if these demands are not met by September 29, 2025, the Administration will use 'every tool' to protect American families from 'abusive drug pricing practices,' with Secretary Kennedy and Administrator Oz prepared for implementation.
Sentiment:Directive
Key Claims:
- An Executive Order, 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,' was signed on May 12, 2025.
- The Executive Order aims to stop 'global freeloading' and guarantee Americans pay the same drug prices as other developed nations.
- Brand name drug prices in the United States are up to three times higher than elsewhere.
- This situation is an 'unacceptable burden on hardworking American families.'
- The Administration rejects proposals that result in 'handouts to industry.'
- Drug manufacturers must provide immediate relief from 'vastly inflated drug prices.'
- European and other developed nations are 'freeloading' off American innovation.
- Bristol Myers Squibb and all drug manufacturers are called to take specific actions within 60 days.
- MFN pricing must be extended to Medicaid for existing drugs.
- MFN pricing must be guaranteed for newly-launched drugs for Medicare, Medicaid, and commercial payers.
- Increased revenues from abroad must be returned to American patients and taxpayers.
- Direct Purchasing at MFN Pricing through DTC and/or DTB models must be provided.
- Secretary Kennedy and Administrator Oz are ready to implement these terms.
- If manufacturers refuse to comply, the Administration will deploy 'every tool' to protect American families from 'abusive drug pricing practices.'
- Americans are demanding lower drug prices.
- Binding commitments are expected by September 29, 2025.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:6/10
Summary:The White House, on July 31, 2025, sent a letter to Novo Nordisk, outlining an Executive Order signed on May 12, 2025, that mandates drug manufacturers adopt Most-Favored-Nation (MFN) pricing for American patients, including for existing drugs via Medicaid and for new drugs for all payers. The letter claims that American patients currently pay up to three times more for brand-name drugs due to global freeloading and demands that increased revenues from higher prices charged abroad be repatriated to benefit American patients and taxpayers. It instructs manufacturers to implement direct purchasing at MFN pricing and warns that non-compliance by September 29, 2025, will result in the deployment of every available tool.
Sentiment:Directive
Key Claims:
- An Executive Order, 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,' was signed on May 12, 2025.
- Brand name drug prices in the United States are up to three times higher than in other developed nations due to 'global freeloading.'
- Drug manufacturers must extend Most-Favored-Nation (MFN) pricing to Medicaid for their full portfolio of existing drugs.
- Drug manufacturers must guarantee MFN pricing for newly-launched drugs to Medicare, Medicaid, and commercial payers.
- Increased revenues obtained abroad must be repatriated to lower drug prices for American patients and taxpayers.
- Manufacturers must provide for direct purchasing at MFN pricing through Direct-to-Consumer (DTC) and/or Direct-to-Business (DTB) distribution models for high-volume, high-rebate prescription drugs.
- Refusal to comply will result in the deployment of 'every tool in our arsenal to protect American families from continued abusive drug pricing practices.'
- Binding commitments to achieve these goals are required by September 29, 2025.
- Secretary Kennedy and Administrator Oz are part of the team ready to implement these terms.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:1/10
Potential Global Cross-Asset Impact:6/10
Summary:A letter from the White House dated July 31, 2025, sent to Amgen, demands that drug manufacturers implement actions within 60 days, by September 29, 2025, to lower prescription drug prices for American patients to Most-Favored-Nation rates. The letter asserts that the US currently pays significantly more for brand name drugs than other developed nations due to 'global freeloading' and highlights an Executive Order signed on May 12, 2025, aimed at addressing this disparity.
Sentiment:Directive
Key Claims:
- An Executive Order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients' was signed on May 12, 2025.
- Brand name drug prices in the United States are up to three times higher than elsewhere, attributed to 'global freeloading' and an 'unacceptable burden' on American families.
- Amgen and all manufacturers are called upon to implement specific actions within 60 days to address inflated drug prices.
- Required actions include extending Most-Favored-Nation (MFN) pricing to Medicaid, guaranteeing MFN pricing for newly-launched drugs, returning increased revenues from abroad to American patients and taxpayers, and providing for direct purchasing at MFN pricing.
- The administration is prepared to deploy 'every tool in our arsenal' to protect American families from 'abusive drug pricing practices' if manufacturers do not comply.
- The deadline for achieving these goals is September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:2/10
Potential Global Cross-Asset Impact:7/10
« Previous
Page 1 of 1
Next »